Severe Respiratory Diseases
Severe respiratory diseases
Around 100,000 people worldwide suffer from Cystic Fibrosis, the most common severe genetic disease. This multi-organ disease mainly affects the lungs, which are hit by chronic infections and inflammations that cause their progressive deterioration.
*Sources: ECFS Patient Registry, Report 2015
200
New cases of Cystic Fibrosis every year in Italy
Source: ECFS Patient Registry, Report 2015
48%
Cases of Cystic Fibrosis affecting children in Europe
Source: ECFS Patient Registry, Report 2015
We want to develop treatments that play a key role in treating Cystic Fibrosis, as well as in managing severe respiratory diseases
Zambon has initiated two pivotal trials for patients suffering from bronchiectases
PIPELINE
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Phase 3
US: CMS & I-Neb for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase 3
EU: CMS & I-Neb for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase 2
US: CMS & I-Neb Cystic Fibrosis (CF)
OUR DIRECT PRESENCE
I-Neb: an innovative inhaler for treating bronchial infections
I-Neb is an innovative medical device developed by Philips in partnership with Zambon.
Thanks to this device, Zambon continues to support patients and health care professionals in ensuring compliance with treatment.
Alongside research into new innovative drugs, support for patients plays a key role with regard to rare diseases such as Cystic Fibrosis.
PARTNERNING OPPORTUNITIES
Business Development Department
+39 02 66524455
FIND OUT MORE ABOUT OTHER TOPICS
Our focus
Zambon's daily commitment: improving the lives of patients.